IN2009KN04355A - - Google Patents

Download PDF

Info

Publication number
IN2009KN04355A
IN2009KN04355A IN4355KON2009A IN2009KN04355A IN 2009KN04355 A IN2009KN04355 A IN 2009KN04355A IN 4355KON2009 A IN4355KON2009 A IN 4355KON2009A IN 2009KN04355 A IN2009KN04355 A IN 2009KN04355A
Authority
IN
India
Prior art keywords
promoter
poll
useful
rna polymerase
rna
Prior art date
Application number
Inventor
Markus Wolschek
Andrej Egorov
Michael Bergmann
Thomas Muster
Christian Kittel
Original Assignee
Avir Green Hills Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avir Green Hills Biotechnology filed Critical Avir Green Hills Biotechnology
Publication of IN2009KN04355A publication Critical patent/IN2009KN04355A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides a linear expression construct free of any conventional amplification and/or selection sequences comprising an RNA polymerase I (poll) promoter and a poll termination signal, inserted between a RNA polymerase Il (polll) promoter and a polyadenylation signal useful for the expression of segments of viral RNA, preferably influenza viruses. The inventive construct is useful for efficient and fast production of viral particles, especially for producing vaccine formulations for the treatment of epidemic and/or pandemic diseases.
IN4355KON2009 2007-06-27 2008-06-26 IN2009KN04355A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94665107P 2007-06-27 2007-06-27
EP07450177A EP2045323A1 (en) 2007-10-05 2007-10-05 Linear expression constructs for production of influenza virus particles
PCT/EP2008/058182 WO2009000891A2 (en) 2007-06-27 2008-06-26 Linear expression constructs for production of influenza virus particles

Publications (1)

Publication Number Publication Date
IN2009KN04355A true IN2009KN04355A (en) 2015-07-10

Family

ID=39099653

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4355KON2009 IN2009KN04355A (en) 2007-06-27 2008-06-26

Country Status (9)

Country Link
US (1) US20100129399A1 (en)
EP (2) EP2045323A1 (en)
CN (1) CN101952427A (en)
AU (1) AU2008267180B2 (en)
CA (1) CA2689569C (en)
EA (1) EA017456B1 (en)
IN (1) IN2009KN04355A (en)
NZ (1) NZ582102A (en)
WO (1) WO2009000891A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091510B2 (en) 2007-03-21 2015-07-28 Schott Corporation Transparent armor system and method of manufacture
EP2072058A1 (en) 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
EP2233568A1 (en) * 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
EA021009B1 (en) 2009-05-21 2015-03-31 Новартис Аг REVERSE GENETICS USING NON-ENDOGENOUS pol I PROMOTERS
CN104862335A (en) * 2009-07-31 2015-08-26 诺华股份有限公司 Reverse genetics systems
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
CN103237890A (en) * 2010-06-02 2013-08-07 巴克斯特保健股份有限公司 Methods and helper viruses for producing RNA viruses
CN102495208B (en) * 2011-10-24 2014-03-26 山东省农业科学院畜牧兽医研究所 Avian influenza virus RT-PCR (reverse transcription-polymerase chain reaction) kit
WO2013067652A1 (en) * 2011-11-10 2013-05-16 Beijing Advaccine Biotechnology Co., Ltd. Facilitator-dna combination vaccine
CN103608453B (en) 2012-03-02 2018-07-24 思齐乐 Influenza virus re-matches
KR20150110494A (en) 2012-12-03 2015-10-02 노파르티스 아게 Reassortant influenza a viren
SG11201507454XA (en) 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
CN105722976A (en) 2013-06-06 2016-06-29 诺华股份有限公司 Influenza virus reassortment
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (en) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 Influenza potency assays
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4837827B2 (en) * 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン Novel virus propagation method and interferon-deficient culture medium therefor
DE69937999T2 (en) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag INTERFERON INDUCING GENETICALLY MODIFIED ATTENUATED VIRUSES
US6280977B1 (en) * 1999-03-24 2001-08-28 Gene Therapy Systems Method for generating transcriptionally active DNA fragments
DE122008000035I1 (en) * 1999-04-06 2009-05-20 Wisconsin Alumni Res Found RECOMBINANT INFLUENZA VIRUSES FOR VACCINATION AND GENE THERAPY
ES2278621T5 (en) * 1999-07-14 2011-02-02 Mount Sinai School Of Medicine Of New York University IN VITRO RECONSTRUCTION OF VIRUS ARN SEGMENTS OF NEGATIVE POLARITY.
ES2319864T3 (en) * 2000-04-28 2009-05-14 St. Jude Children's Research Hospital DNA TRANSFECTION SYSTEM FOR THE GENERATION OF NEGATIVE CHAIN RNA INFECTIOUS VIRUSES.
DK1499348T3 (en) * 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
CA2551489C (en) * 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
DK2497492T3 (en) * 2004-06-01 2018-11-26 Icahn School Med Mount Sinai Genetically modified swine influenza virus and its applications
EA200701097A1 (en) * 2004-11-19 2007-10-26 Висконсин Эламни Рисёч Фаундэйшн RECOMBINANT VECTORS OF THE INFLUENZA VIRUS WITH TANDEM TRANSCRIPTION UNITS
US8043856B2 (en) * 2007-06-14 2011-10-25 Wisconsin Alumni Research Foundation Adenoviral vectors for influenza virus production

Also Published As

Publication number Publication date
EP2160462A2 (en) 2010-03-10
CN101952427A (en) 2011-01-19
US20100129399A1 (en) 2010-05-27
CA2689569C (en) 2020-10-27
CA2689569A1 (en) 2008-12-31
WO2009000891A2 (en) 2008-12-31
AU2008267180B2 (en) 2014-07-10
AU2008267180A1 (en) 2008-12-31
WO2009000891A3 (en) 2009-02-26
EP2045323A1 (en) 2009-04-08
EA017456B1 (en) 2012-12-28
NZ582102A (en) 2012-06-29
EA201000076A1 (en) 2010-06-30
EP2160462B1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
IN2009KN04355A (en)
MXPA06013411A (en) Process for the production of an influenza vaccine.
EP4385567A3 (en) Methods and compositions for rna-guided treatment of hiv infection
MX342639B (en) High titer recombinant influenza viruses for vaccines and gene therapy.
TW200636070A (en) Rescue of influenza virus
NZ606087A (en) Influenza vaccine
MX2018008135A (en) Influenza nucleic acid molecules and vaccines made therefrom.
WO2014193716A3 (en) Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer
WO2007053696A3 (en) Rnai inhibition of influenza virus replication
EA200970013A1 (en) VACCINATION AGAINST FLU BY THE SCHEME OF MULTIPLE INTRODUCTION WITH THE USE OF UNDEFINED DOSE
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2009080806A3 (en) Modified influenza virus
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
TW200732476A (en) Functional influenza virus like particles (VLPs)
AR023166A1 (en) VACCINE OF THE HUMAN PAPILOMA VIRUS WITH DISASSEMBLED AND REASSEMBLED VIRUS TYPE PARTICLES
NZ602504A (en) Antiviral vaccines with improved cellular immunogenicity
PH12013502442A1 (en) Inactivated dengue virus vaccine
EP4126032A4 (en) Universal influenza vaccine using nucleoside-modifield mrna
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
CA3267272A1 (en) Influenza virus vaccines
NZ597601A (en) Treatment and prevention of influenza
EA201171370A1 (en) UNIVERSAL METHODS FOR DETERMINATION OF FLU VIRUSES
AU2016204276A1 (en) Methods for producing virus particles with simplified glycosylation of surface proteins
WO2011138682A3 (en) Organic peroxide compounds for microorganism inactivation
TW200508247A (en) Sars